Table 1.
Number of monthly prescriptions of different therapy groups throughout the study period
| Therapy | 2018 | 2019 | 2020 | 2021f | Whole study periodg |
|---|---|---|---|---|---|
| First linea | 11.8 (5.3) | 12.7 (4.67) | 10.3 (3.91) | 11.2 (4.02) | 11.6 (4.64) |
| Anti-CD20b | 5.7 (2.39) | 13.8 (6.70) | 9.8 (4.47) | 6.4 (3.71) | 9.8 (5.80) |
| Other second linec | 5.5 (2.64) | 3.5 (1.51) | 4.1 (1.92) | 5.6 (2.07) | 4.4 (2.19) |
| Natalizumabd | 1.1 (0.99) | 1.0 (1.13) | 1.8 (1.27) | 2.6 (1.82) | 1.3 (1.17) |
| All therapiese | 23.0 (7.97) | 30 (6.98) | 24.1 (6.99) | 23.2 (45) | 25.7 (7.77) |
All reported values are: mean (standard deviation)
aFirst-line therapies include interferon, acetate glatiramer, teriflunomide, and dimethyl fumarate
bAnti-CD20 therapies include rituximab and ocrelizumab
cOther second-line therapies include natalizumab, fingolimod, cladribine, and alemtuzumab
dOnly natalizumab prescriptions
eAll therapies include first-line, anti-CD20 and other second-line therapies
fIncludes data from January 1 to May 31, 2021
gIncludes data from 2018, 2019, and 2020